PharmAla named an Intellectual Property Ontario Client
22 févr. 2024 08h55 HE
|
PharmAla Biotech
PharmAla recieves a non-dilutive grant from IP Ontario (IPON) to support its patent work in international markets.
PharmAla Data to be Published in ACS Chemical Neuroscience
20 févr. 2024 08h55 HE
|
PharmAla Biotech
PharmAla's drug discovery data to be published in ACS Chemical Neuroscience; PharmAla presents data at ISRP Conference in New Orleans
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
12 févr. 2024 07h00 HE
|
Optimi Health Corp.
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD
09 févr. 2024 19h30 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
The FDA has accepted Lykos Therapeutics' New Drug Application, supported by two decades of research incubated by MAPS, for MDMA-assisted therapy for PTSD.
PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development
09 févr. 2024 08h10 HE
|
PharmAla Biotech
PharmAla signs all-cash agreement to consult for Red Light Holland
Optimi Announces Non-Brokered Private Placement
08 févr. 2024 07h30 HE
|
Optimi Health Corp.
Optimi Announces Non-Brokered Private Placement
Optimi Health To Host MDMA Educational Quality Assurance Webinar For Clinicians And Practitioners
06 févr. 2024 07h30 HE
|
Optimi Health Corp.
Highlights: Optimi Chief Science and Quality Assurance experts to provide in-depth access into the Company’s safety and quality standards.Optimi experts will address critical inquiries which still...
PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
31 janv. 2024 10h58 HE
|
PharmAla Biotech
PharmAla releases Profitable Q1 Interim Financial Statement, and will host investor webinar to discuss prominent changes to the business & FDA timelines
Huxley Health Inc. Provides Corporate Update - Appoints Bruce Linton as Chairman
30 janv. 2024 08h30 HE
|
Huxley Health Inc
Huxley Health Inc. provides corporate update including groundbreaking IP filings and appointment of Mr. Bruce Linton as Chairman.
PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada
25 janv. 2024 12h09 HE
|
PharmAla Biotech
PharmAla granted a Health Canada Controlled Drugs and Substances Dealer's License